SCHEMBL15923524

SCHEMBL15923524

NC(=O)c1cc(-n2ccc(I)n2)ccn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 2/20 0.37
SCN9A Q15858 1/20 0.36
ADORA3 P0DMS8 1/20 0.35
TSHR P16473 1/20 0.35
MC4R P32245 1/20 0.35
ADRA1A P35348 1/20 0.35
MC3R P41968 1/20 0.35
ELOVL1 Q9BW60 3/20 0.33
GSK3B P49841 2/20 0.33
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
MAP3K14 Q99558 1/20 0.32
TGFBR1 P36897 1/20 0.32
LCK P06239 1/20 0.31
OPRM1 P35372 2/20 0.31
KDM4E B2RXH2 1/20 0.31
KDM6B O15054 1/20 0.31
TET3 O43151 1/20 0.31
KDM4A O75164 1/20 0.31
BBOX1 O75936 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15924055 0.88 KDM4E (0.45) ELOVL1KDM4EKDM6BTET3KDM4A
SCHEMBL15923985 0.83 ALDH1A1 (0.40) ELOVL1KDM4EKDM6BALDH1A1KDM5A
SCHEMBL27764122 0.74 RECQL (0.34)
SCHEMBL15924047 0.74 ELOVL1 (0.40) IRAK4ELOVL1KDM4EALDH1A1MAPT
SCHEMBL19918058 0.71 ADORA3 (0.45) ADORA3TSHRMC4RADRA1AMC3R
SCHEMBL15825104 0.71 AR (0.43) MAPT
SCHEMBL15825472 0.71 ELOVL1 (0.43) IRAK4ELOVL1TGFBR1OPRM1
SCHEMBL14247709 0.69 SCN9A (0.42) SCN9AADORA3TSHRMC4RADRA1A
SCHEMBL15824337 0.69 MTOR (0.39) ELOVL1KDM4EALDH1A1MAPTKMT2A
SCHEMBL16517045 0.69 MAP3K14 (0.47) IRAK4SCN9AADORA3TSHRMC4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2934538-B1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME (US) 2021-03-31 EP disclosed
US-9708308-B2 Factor IXa inhibitors MERCK SHARP DOHME CORP. (US) 2017-07-18 US disclosed
US-20150322056-A1 Factor IXa Inhibitors MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-11-12 US disclosed
EP-2934538-A1 FACTOR IXA INHIBITORS Merck Sharp & Dohme Corp. (US) 2015-10-28 EP disclosed
WO-2014120346-A1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME CORP. (US) 2014-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322056-A1 Factor IXa Inhibitors F9, F12, F8 IRAK4 3608/4885SCN9A 95/4885ADORA3 810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.